Vanguard Group
MLYS icon

Vanguard Group’s Mineralys Therapeutics MLYS Stock Holding History

Vanguard Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$122M Buy
3,352,880
+333,881
+11% +$13.4M ﹤0.01% 1786
2025
Q3 		$114M Buy
3,018,999
+692,550
+30% +$15M ﹤0.01% 1800
2025
Q2 		$31.5M Buy
2,326,449
+290,943
+14% +$4.22M ﹤0.01% 2335
2025
Q1 		$32.3M Buy
2,035,506
+603,464
+42% +$6.94M ﹤0.01% 2282
2024
Q4 		$17.6M Buy
1,432,042
+68,811
+5% +$900K ﹤0.01% 2643
2024
Q3 		$16.5M Buy
1,363,231
+144,169
+12% +$1.75M ﹤0.01% 2689
2024
Q2 		$14.3M Buy
1,219,062
+236,130
+24% +$2.97M ﹤0.01% 2726
2024
Q1 		$12.7M Buy
982,932
+4,952
+0.5% +$61.2K ﹤0.01% 2832
2023
Q4 		$8.41M Buy
977,980
+40,342
+4% +$317K ﹤0.01% 3049
2023
Q3 		$8.92M Buy
937,638
+11,629
+1% +$152K ﹤0.01% 2943
2023
Q2 		$15.8M Buy
926,009
+634,281
+217% +$9.48M ﹤0.01% 2694
2023
Q1 		$4.57M Buy
+291,728
New +$4.91M ﹤0.01% 3354

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Vanguard Group's MLYS Position: Q4 2025 in Review

Vanguard Group increased its Mineralys Therapeutics (MLYS) stake by 11% in Q4 2025, buying an estimated $13.4M and bringing the position to 3,352,880 shares worth $122M. The position accounts for ﹤0.01% of the portfolio, ranked #1786.

Vanguard Group first reported a position in MLYS in Q1 2023 and has held it in 12 quarters since. 223 funds tracked by Wall St. Rank hold MLYS as of Q4 2025.

  • Vanguard Group held 3,352,880 shares of Mineralys Therapeutics worth $122M as of Q4 2025.
  • Vanguard Group bought 333,881 Mineralys Therapeutics shares in Q4 2025, an estimated $13.4M.
  • Mineralys Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1786 holding.
  • Vanguard Group first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • 223 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.